Orexo AB (publ) (FRA:C5G)

Germany flag Germany · Delayed Price · Currency is EUR
2.275
-0.040 (-1.73%)
At close: Dec 4, 2025
78.01%
Market Cap 78.32M
Revenue (ttm) 49.16M
Net Income (ttm) -18.25M
Shares Out n/a
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 60
Open 2.275
Previous Close 2.315
Day's Range 2.275 - 2.275
52-Week Range 1.092 - 3.825
Beta n/a
RSI 32.45
Earnings Date Feb 5, 2026

About Orexo AB

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and ... [Read more]

Industry Pharmaceutical Preparations
Founded 1994
Employees 110
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol C5G
Full Company Profile

Financial Performance

In 2024, Orexo AB's revenue was 590.00 million, a decrease of -7.64% compared to the previous year's 638.80 million. Losses were -203.00 million, 58.2% more than in 2023.

Financial numbers in SEK Financial Statements

News

There is no news available yet.